Immune Checkpoint Inhibitor Blood Test Launches in the United States

UK-based biotechnology company Oxford Biodynamics has announced the US launch of its clinical blood test predicting the likelihood of response to immune checkpoint inhibitors (ICIs) in patients with cancer.

ICIs are currently used as an alternative to chemotherapy or radiation in the treatment of more than 15 types of cancer, including Hodgkin lymphoma. However, less than 1 in 3 patients derive benefit from ICIs, with many experiencing severe toxicities as well as significant financial burden.

The routine blood test uses a 3D genomic biomarker platform that can build molecular diagnostic classifiers to predict response to therapy, prognosis, diagnosis and subtyping, and residual disease monitoring across a range of indications.

Source: Oxford Biodynamics press release, Feb. 25, 2022.